Ensitrelvir (S-217622) Intermediate CAS 1360105-53-8 Purity >98.0% COVID-19

Short Description:

Chemical Name: 1,3,5-Triazine-2,4(1H,3H)-dione, 3-(1,1-dimethylethyl)-6-(ethylthio)-

CAS: 1360105-53-8

Purity: >98.0% (HPLC)

Intermediate of Ensitrelvir (S-217622), COVID-19

High Quality, Commercial Production

E-Mail: alvin@ruifuchem.com

Send email to us

Product Detail

Product Tags

Description:

Commercial Supply Ensitrelvir (S-217622) Intermediates:
S-Ethylisothiourea Hydrobromide CAS 1071-37-0
2,4,5-Trifluorobenzyl Bromide CAS 157911-56-3
Trimethyloxonium Tetrafluoroborate CAS 420-37-1
6-Chloro-2-methyl-2H-indazol-5-amine CAS 1893125-36-4
3-(Chloromethyl)-1-methyl-1H-1,2,4-triazole hydrochloride CAS 135206-76-7
1,3,5-Triazine-2,4(1H,3H)-dione, 3-(1,1-dimethylethyl)-6-(ethylthio)- CAS 1360105-53-8

Chemical Properties:

Chemical Name	1,3,5-Triazine-2,4(1H,3H)-dione, 3-(1,1-dimethylethyl)-6-(ethylthio)-
Synonyms	3-tert-butyl-6-(ethylthio)-1,3,5-triazine-2,4(1H,3H)-dione
CAS Number	1360105-53-8
CAT Number	RF-PI1504
Stock Status	In Stock
Molecular Formula	C9H15N3O2S
Molecular Weight	229.3
Brand	Ruifu Chemical

Specifications:

Item	Specifications
Purity	>98.0%
Loss on Drying	<1.00%
Total Impurities	<2.00%
Test Standard	Enterprise Standard
Usage	Intermediate of Ensitrelvir (S-217622), COVID-19

Package & Storage:

Package: Bottle, Aluminium foil bag, 25kg/Cardboard Drum, or according to customer's requirement.

Storage Condition: Store in sealed containers at cool and dry place; Protect from light and moisture.

Advantages:

FAQ:

Application:

3-(Chloromethyl)-1-methyl-1H-1,2,4-triazole hydrochloride (CAS: 135206-76-7) is an intermediate of Ensitrelvir (S-217622). Ensitrelvir is an antiviral drug developed by Shionogi in partnership with Hokkaido University, which acts as an orally active 3C-like protease inhibitor for the treatment of COVID-19 infection. It is taken by mouth, and has been successfully tested against the recently emerged Omicron variant. It became the first Japanese domestic pill to treat COVID-19, third to be regulatorally approved in Japan; in February 2022.